Imperial College London

Dr Benjamin Mullish

Faculty of MedicineDepartment of Metabolism, Digestion and Reproduction

NIHR Clinical Lecturer
 
 
 
//

Contact

 

b.mullish

 
 
//

Location

 

Queen Elizabeth the Queen Mother Wing (QEQM)St Mary's Campus

//

Summary

 

Publications

Publication Type
Year
to

191 results found

Michael DR, Davies TS, Jack AA, Masetti G, Marchesi JR, Wang D, Mullish BH, Plummer SFet al., 2021, Daily supplementation with the Lab4P probiotic consortium induces significant weight loss in overweight adults, Scientific Reports, Vol: 11

<jats:title>Abstract</jats:title><jats:p>This 9-month randomised, parallel, double-blind, single-centre, placebo-controlled study (PROBE, ISRCTN18030882) assessed the impact of probiotic supplementation on bodyweight. Seventy overweight Bulgarian participants aged 45–65 years with BMI 25–29.9 kg/m<jats:sup>2</jats:sup> received a daily dose of the Lab4P probiotic comprising lactobacilli and bifidobacteria (50 billion cfu/day). Participants maintained their normal diet and lifestyle over the duration of the study. The primary outcome was change from baseline in body weight and secondary outcomes included changes in waist circumference, hip circumference and blood pressure. A significant between group decrease in body weight (3.16 kg, 95% CI 3.94, 2.38, <jats:italic>p</jats:italic> &lt; 0.0001) was detected favouring the probiotic group. Supplementation also resulted in significant between group decreases in waist circumference (2.58 cm, 95% CI 3.23, 1.94, <jats:italic>p</jats:italic> &lt; 0.0001) and hip circumference (2.66 cm, 95% CI 3.28, 2.05, <jats:italic>p</jats:italic> &lt; 0.0001) but no changes in blood pressure were observed. These findings support the outcomes of a previous shorter-term Lab4P intervention study in overweight and obese participants (PROMAGEN, ISRCTN12562026). We conclude that Lab4P has consistent weight modulation capability in free-living overweight adults.</jats:p>

Journal article

Smith PJ, 2021, GI highlights from the literature, Gut, Vol: 70, Pages: 1194-1195, ISSN: 0017-5749

Journal article

Mullish BH, Allegretti JR, 2021, The contribution of bile acid metabolism to the pathogenesis of Clostridioides difficile infection, Therapeutic Advances in Gastroenterology, ISSN: 1756-2848

Journal article

Ghani R, Mullish BH, McDonald JAK, Ghazy A, Williams HRT, Brannigan ET, Mookerjee S, Satta G, Gilchrist M, Duncan N, Corbett R, Innes AJ, Pavlů J, Thursz MR, Davies F, Marchesi JRet al., 2021, Disease Prevention Not Decolonization: A Model for Fecal Microbiota Transplantation in Patients Colonized With Multidrug-resistant Organisms, Clinical Infectious Diseases, Vol: 72, Pages: 1444-1447, ISSN: 1058-4838

<jats:title>Abstract</jats:title> <jats:p>Fecal microbiota transplantation (FMT) yields variable intestinal decolonization results for multidrug-resistant organisms (MDROs). This study showed significant reductions in antibiotic duration, bacteremia, and length of stay in 20 patients colonized/infected with MDRO receiving FMT (compared with pre-FMT history, and a matched group not receiving FMT), despite modest decolonization rates.</jats:p>

Journal article

Mullish BH, Alexander JL, Segal JP, 2021, Microbiota and faecal microbiota transplant, Microbiota in Health and Disease, ISSN: 2704-8845

Journal article

Gupta S, Mullish BH, Allegretti JR, 2021, Fecal microbiota transplantation: the evolving risk landscape, American Journal of Gastroenterology, Vol: 116, Pages: 647-656, ISSN: 0002-9270

Fecal microbiota transplantation (FMT) has been recommended in clinical guidelines for the treatment for recurrent Clostridioides difficile infection (CDI). However, it is considered investigational by most regulatory agencies. As the adoption of FMT increased from a small group of CDI experts alone to more widespread use, there has been a corresponding increase in concern regarding potential risk. FMT is largely considered a safe procedure, though risks described range from mild gastrointestinal symptoms to serious infection. Currently, there is variability in how ‘FMT’ is characterized specifically with regards to testing approach, which, in turn, impacts the risk profile. This has been highlighted by the rare cases of multidrug-resistant organisms, Shiga toxin-producing E. coli and enteropathogenic E. coli recently reported, where these organisms were not screened. These cases have prompted additional screening mandates from the FDA, which has maintained its policy of enforcement discretion for the use of FMT for CDI not responding to standard therapy. Here, we examine the evolving risk landscape of FMT.

Journal article

Smith PJ, 2021, GI highlights from the literature, Gut, Vol: 70, Pages: 803-804, ISSN: 0017-5749

Journal article

Ianiro G, Mullish BH, Hvas CL, Segal JP, Kuijper EJ, Costello SP, Kelly CR, Allegretti JR, Fischer M, Iqbal TH, Satokari R, Kao D, van Prehn J, Ng SC, Bibbò S, Baunwall SMD, Quraishi MN, Sokol H, Zhang F, Keller J, Masucci L, Quaranta G, Kassam Z, Sanguinetti M, Tilg H, Gasbarrini A, Cammarota Get al., 2021, SARS-CoV-2 vaccines and donor recruitment for FMT, The Lancet Gastroenterology & Hepatology, Vol: 6, Pages: 264-266, ISSN: 2468-1253

Journal article

Mullish BH, Marchesi JR, McDonald JAK, Pass DA, Masetti G, Michael DR, Plummer S, Jack AA, Davies TS, Hughes TR, Wang Det al., 2021, Probiotics reduce self-reported symptoms of upper respiratory tract infection in overweight and obese adults: should we be considering probiotics during viral pandemics?, Gut Microbes, ISSN: 1949-0976

Journal article

Gilca-Blanariu GE, Stefanescu G, Girleanu I, Iqbal T, Segal J, Mullish B, Quraishi MN, Keller J, Molnar T, Megraud F, Dumitrascu D, Manuc M, Iancu LS, Marica C, Gheorghe C, Manzoor S, Trifan Aet al., 2021, Romanian National Guideline on Translating Fecal Microbiota Transplantation Applications related to Clostridioides difficile Infections into the Local Clinical Practice, Journal of Gastrointestinal and Liver Diseases, Vol: 30, Pages: 147-163, ISSN: 1841-8724

<jats:p>Fecal microbiota transplantation involves the infusion of intestinal microorganisms via the transfer of a stool from a healthy individual into a diseased individual, with the intent of restoring normal intestinal flora. Fecal transplant is proposed for the treatment of refractory Clostridioides difficile infection. At present, recurrent Clostridioides difficile infection is the only indication supported by solid scientific evidence. Regulations by healthcare authorities vary among different countries. Considering that Romania does not have an available national guideline to offer standardization, this paper aimed to create a national fecal microbiota transplantation guideline concerning indications, techniques and donor screening, developed by international and local scientific working groups.</jats:p>

Journal article

Nathwani R, Kockerling D, Mullish BH, Cole A, Lemoine M, Antoniades CG, Thursz MR, Dhar Aet al., 2021, Non-selective beta-blocker use in cirrhosis: the additional benefit in preventing secondary infections, Frontline Gastroenterology, ISSN: 2041-4137

Journal article

Mullish BH, Quraishi MN, Segal JP, Ianiro G, Iqbal THet al., 2021, The gut microbiome: what every gastroenterologist needs to know, Frontline Gastroenterology, Vol: 12, Pages: 118-127, ISSN: 2041-4137

<jats:p>The mucosal surfaces of the body are characterised by complex, specialised microbial communities, often referred to as the <jats:italic>microbiome</jats:italic>. However, only much more recently—with the development of technologies allowing exploration of the composition and functionality of these communities—has meaningful research in this area become feasible. Over the past few years, there has been rapid growth in interest in the gut microbiome in particular, and its potential contribution to gastrointestinal and liver disease. This interest has already extended beyond clinicians to pharmaceutical companies, medical regulators and other stakeholders, and is high profile among patients and the lay public in general. Such expansion of knowledge holds the intriguing potential for translation into novel diagnostics and therapeutics; however, being such a nascent field, there remain many uncertainties, unanswered questions and areas of debate.</jats:p>

Journal article

Nathwani R, Mullish BH, Kockerling D, Cole A, Selvapatt N, Dhar Aet al., 2021, Review of rifaximin: a summary of the current evidence and its benefits beyond its licensed use, European Medical Journal, ISSN: 2397-6764

Antibiotic resistance in patients with cirrhosis continues to draw significant attention. With a propensity to frequent hospitalisations, cirrhotics are subject to frequent antibiotic prescription. This increases their risk of developing resistance to one or more antimicrobial agents, making management of their condition particularly challenging. Despite advancements being made in the management of liver disease, mortality rates continue to rise; almost fivefold in those under 65 years, whilst remaining the leading cause of death in those between the ages of 35-49 years. Urgent alternative therapeutic options to prevent disease progression and cirrhosis-associated complications are urgently required. Rifaximin is one such example, with its use in patients with cirrhosis demonstrating additional benefits beyond its current licensed use. Its current licensed use in the UK is for the prevention of hepatic encephalopathy and traveller’s diarrhoea; however, its use in the context of enteric-driven pathologies has been explored. Through rifaximin’s key central action as a broad-spectrum antimicrobial, it has the ability to modulate the gut-liver axis via removal of gut microbial products associated with the progression of cirrhosis and its sequalae. The benefits of rifaximin use continues to gather some momentum, given its non-absorbable nature and well tolerated side-effect profile, and these require consideration. With broad spectrum antimicrobial properties, its use may assist in overcoming the conundrum posed of antibiotic resistance amongst cirrhotics. This literature review discusses the chemical and antimicrobial properties of rifaximin, its licenced indication for use, and its reported benefits beyond this. We also consider concerns regarding rifaximin resistance.

Journal article

NICE, 2021, Faecal microbiota transplant for recurrent or refractory Clostridioides difficile infection, Medtech innovation briefing [MIB247]

Report

Morgan A, Vander Broek C, 2021, Microbiome Strategic Roadmap, Publisher: KTN

Report

Allegretti JR, Kassam Z, Hurtado J, Marchesi JR, Mullish BH, Chiang A, Thompson CC, Cummings BPet al., 2021, Impact of fecal microbiota transplantation with capsules on the prevention of metabolic syndrome among patients with obesity, HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, Vol: 20, Pages: 209-211, ISSN: 1109-3099

Journal article

Huus KE, Frankowski M, Pučić-Baković M, Vučković F, Lauc G, Mullish BH, Marchesi JR, Monaghan TM, Kao D, Finlay BBet al., 2021, Changes in IgA-targeted microbiota following fecal transplantation for recurrent Clostridioides difficile infection, Gut Microbes, Vol: 13, Pages: 1-12, ISSN: 1949-0976

Journal article

Forlano R, Mullish BH, Maurice JB, Thursz MR, Goldin RD, Manousou Pet al., 2021, NAFLD: Time to apply quantitation in liver biopsies as endpoints in clinical trials, Journal of Hepatology, Vol: 74, Pages: 241-242, ISSN: 0168-8278

Journal article

Mullish BH, Michael DR, McDonald JA, Masetti G, Plummer SF, Marchesi JRet al., 2021, Identifying the factors influencing outcome in probiotic studies in overweight and obese patients: host or microbiome?, Gut, Vol: 70, Pages: 225-226

Journal article

Forlano R, Mullish BH, Nathwani R, Dhar A, Thursz MR, Manousou Pet al., 2020, Non-Alcoholic Fatty Liver Disease and Vascular Disease, Current Vascular Pharmacology, Vol: 19, Pages: 269-279, ISSN: 1570-1611

<jats:sec><jats:title /><jats:p>Non-Alcoholic Fatty Liver Disease (NAFLD) represents an increasing cause of liver diseaseworldwide. However, notably, the primary cause of morbidity and mortality in patients with NAFLD iscardiovascular disease (CVD), with fibrosis stage being the strongest disease-specific predictor. It isglobally projected that NAFLD will become increasingly prevalent, especially among children andyounger adults. As such, even within the next few years, NAFLD will contribute considerably to theoverall CVD burden.</jats:p></jats:sec><jats:sec><jats:title /><jats:p>In this review, we discuss the role of NAFLD as an emerging risk factor for CVD. In particular, thisarticle aims to provide an overview of pathological drivers of vascular damage in patients with NAFLD.Moreover, the impact of NAFLD on the development, severity and the progression of subclinical andclinical CVD will be discussed. Finally, the review illustrates current and potential future perspectivesto screen for CVD in this high-risk population.</jats:p></jats:sec>

Journal article

Innes AJ, Ghani R, Mullish BH, Szydlo R, Palanicawandar R, Olavarria E, Apperley JF, Thursz MR, Williams HR, Marchesi JR, Davies F, Pavlu Jet al., 2020, O105. Faecal microbiota transplant (FMT) can reduce the high NRM associated with multi-drug resistant organism (MDRO) colonisation prior to allogeneic HCT., The 46th Annual Meeting of the European Society for Blood and Marrow Transplantation, Publisher: Springer Nature [academic journals on nature.com], Pages: 122-122, ISSN: 0268-3369

Conference paper

Smith PJ, 2020, GI highlights from the literature, Gut, Vol: 69, Pages: 2256-2257, ISSN: 0017-5749

Journal article

Baunwall SMD, Lee MM, Eriksen MK, Mullish BH, Marchesi JR, Dahlerup JF, Hvas CLet al., 2020, Faecal microbiota transplantation for recurrent Clostridioides difficile infection: An updated systematic review and meta-analysis, EClinicalMedicine, Vol: 29-30, Pages: 100642-100642, ISSN: 2589-5370

Journal article

Ovadia C, Perdones-Montero A, Fan HM, Mullish BH, McDonald JAK, Papacleovoulou G, Wahlström A, Ståhlman M, Tsakmaki A, Clarke LCD, Sklavounos A, Dixon PH, Bewick GA, Walters JRF, Marschall H-U, Marchesi JR, Williamson Cet al., 2020, Ursodeoxycholic acid enriches intestinal bile salt hydrolase-expressing Bacteroidetes in cholestatic pregnancy, Scientific Reports, Vol: 10

<jats:title>Abstract</jats:title><jats:p>Ursodeoxycholic acid (UDCA) treatment can reduce itch and lower endogenous serum bile acids in intrahepatic cholestasis of pregnancy (ICP). We sought to determine how it could influence the gut environment in ICP to alter enterohepatic signalling. The gut microbiota and bile acid content were determined in faeces from 35 pregnant women (14 with uncomplicated pregnancies and 21 with ICP, 17 receiving UDCA). Faecal bile salt hydrolase activity was measured using a precipitation assay. Serum fibroblast growth factor 19 (FGF19) and 7α-hydroxy-4-cholesten-3-one (C4) concentrations were measured following a standardised diet for 21 hours. Women with a high ratio of <jats:italic>Bacteroidetes</jats:italic> to <jats:italic>Firmicutes</jats:italic> were more likely to be treated with UDCA (Fisher’s exact test p = 0.0178) than those with a lower ratio. Bile salt hydrolase activity was reduced in women with low <jats:italic>Bacteroidetes</jats:italic>:<jats:italic>Firmicutes</jats:italic>. Women taking UDCA had higher faecal lithocholic acid (p &lt; 0.0001), with more unconjugated bile acids than women with untreated ICP or uncomplicated pregnancy. UDCA-treatment increased serum FGF19, and reduced C4 (reflecting lower bile acid synthesis). During ICP, UDCA treatment can be associated with enrichment of the gut microbiota with <jats:italic>Bacteroidetes</jats:italic>. These demonstrate high bile salt hydrolase activity, which deconjugates bile acids enabling secondary modification to FXR agonists, enhancing enterohepatic feedback via FGF19.</jats:p>

Journal article

Michael DR, Jack AA, Masetti G, Davies TS, Loxley KE, Kerry-Smith J, Plummer JF, Marchesi JR, Mullish BH, McDonald JAK, Hughes TR, Wang D, Garaiova I, Paduchová Z, Muchová J, Good MA, Plummer SFet al., 2020, A randomised controlled study shows supplementation of overweight and obese adults with lactobacilli and bifidobacteria reduces bodyweight and improves well-being, Scientific Reports, Vol: 10

<jats:title>Abstract</jats:title><jats:p>In an exploratory, block-randomised, parallel, double-blind, single-centre, placebo-controlled superiority study (ISRCTN12562026, funded by Cultech Ltd), 220 Bulgarian participants (30 to 65 years old) with BMI 25–34.9 kg/m<jats:sup>2</jats:sup> received Lab4P probiotic (50 billion/day) or a matched placebo for 6 months. Participants maintained their normal diet and lifestyle. Primary outcomes were changes in body weight, BMI, waist circumference (WC), waist-to-height ratio (WtHR), blood pressure and plasma lipids. Secondary outcomes were changes in plasma C-reactive protein (CRP), the diversity of the faecal microbiota, quality of life (QoL) assessments and the incidence of upper respiratory tract infection (URTI). Significant between group decreases in body weight (1.3 kg, <jats:italic>p</jats:italic> &lt; 0.0001), BMI (0.045 kg/m<jats:sup>2</jats:sup>, <jats:italic>p</jats:italic> &lt; 0.0001), WC (0.94 cm, <jats:italic>p</jats:italic> &lt; 0.0001) and WtHR (0.006, <jats:italic>p</jats:italic> &lt; 0.0001) were in favour of the probiotic. Stratification identified greater body weight reductions in overweight subjects (1.88%, <jats:italic>p</jats:italic> &lt; 0.0001) and in females (1.62%, <jats:italic>p</jats:italic> = 0.0005). Greatest weight losses were among probiotic hypercholesterolaemic participants (−2.5%, <jats:italic>p</jats:italic> &lt; 0.0001) alongside a significant between group reduction in small dense LDL-cholesterol (0.2 mmol/L, <jats:italic>p</jats:italic> = 0.0241). Improvements in QoL and the incidence rate ratio of URTI (0.60, <jats:italic>p</jats:italic> &lt;&thins

Journal article

Miguens Blanco J, Selvarajah U, Liu Z, Mullish BH, Alexander J, McDonald J, Abraham S, Marchesi Jet al., 2020, Identification of New Associations Between Psoriatic Arthritis and the Gut Microbiota. the Mi-PART, a Phenomic Study, ACR Convergence 2020, Publisher: Wiley, ISSN: 2326-5205

Conference paper

Martinez-Gili L, McDonald JAK, Liu Z, Kao D, Allegretti JR, Monaghan TM, Barker GF, Miguéns Blanco J, Williams HRT, Holmes E, Thursz MR, Marchesi JR, Mullish BHet al., 2020, Understanding the mechanisms of efficacy of fecal microbiota transplant in treating recurrent Clostridioides difficile infection and beyond: the contribution of gut microbial-derived metabolites, Gut Microbes, Vol: 12, Pages: 1810531-1810531, ISSN: 1949-0976

Journal article

Allegretti JR, Kelly CR, Grinspan A, Mullish BH, Hurtado J, Carrellas M, Marcus J, Marchesi JR, McDonald JAK, Gerardin Y, Silverstein M, Pechlivanis A, Barker GF, Miguens Blanco J, Alexander JL, Gallagher KI, Pettee W, Phelps E, Nemes S, Sagi SV, Bohm M, Kassam Z, Fischer Met al., 2020, Inflammatory Bowel Disease Outcomes Following Fecal Microbiota Transplantation for Recurrent C. difficile Infection, Inflammatory Bowel Diseases, ISSN: 1078-0998

<jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background</jats:title> <jats:p>Recurrent Clostridioides difficile infection (CDI) in patients with inflammatory bowel disease (IBD) is a clinical challenge. Fecal microbiota transplantation (FMT) has emerged as a recurrent CDI therapy. Anecdotal concerns exist regarding worsening of IBD activity; however, prospective data among IBD patients are limited.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>Secondary analysis from an open-label, prospective, multicenter cohort study among IBD patients with 2 or more CDI episodes was performed. Participants underwent a single FMT by colonoscopy (250 mL, healthy universal donor). Secondary IBD-related outcomes included rate of de novo IBD flares, worsening IBD, and IBD improvement—all based on Mayo or Harvey-Bradshaw index (HBI) scores. Stool samples were collected for microbiome and targeted metabolomic profiling.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>Fifty patients enrolled in the study, among which 15 had Crohn’s disease (mean HBI, 5.8 ± 3.4) and 35 had ulcerative colitis (mean partial Mayo score, 4.2 ± 2.1). Overall, 49 patients received treatment. Among the Crohn’s disease cohort, 73.3% (11 of 15) had IBD improvement, and 4 (26.6%) had no disease activity change. Among the ulcerative colitis cohort, 62% (22 of 34) had IBD improvement, 29.4% (11 of 34) had no change, and 4% (1 of 34) experienced a de novo flare. Alpha diversity significantly increased post-FMT, and ulcerative colitis patients became more similar to the donor than Crohn’s disease patients (P = 0.04).</jats:p>

Journal article

Allegretti JR, Kelly CR, Grinspan A, Mullish BH, Kassam Z, Fischer Met al., 2020, Outcomes of Fecal Microbiota Transplantation in Patients With Inflammatory Bowel Diseases and Recurrent Clostridioides difficile Infection, Gastroenterology, Vol: 159, Pages: 1982-1984, ISSN: 0016-5085

Journal article

Craven LJ, McIlroy JR, Mullish BH, Marchesi JRet al., 2020, Letter: Intestinal microbiota transfer – Updating the nomenclature to increase acceptability, Alimentary Pharmacology and Therapeutics, Vol: 52, Pages: 1622-1623, ISSN: 0269-2813

This article is linked to Lai et al paper. To view this article, visit https://doi.org/10.1111/apt.15116

Journal article

This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.

Request URL: http://wlsprd.imperial.ac.uk:80/respub/WEB-INF/jsp/search-html.jsp Request URI: /respub/WEB-INF/jsp/search-html.jsp Query String: respub-action=search.html&id=00350833&limit=30&person=true